Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a large growth in short interest in February. As of February 28th, there was short interest totalling 344,000 shares, a growth of 22.1% from the February 13th total of 281,700 shares. Approximately 7.5% of the shares of the stock are sold short. Based on an average daily volume of 236,200 shares, the short-interest ratio is currently 1.5 days.

Vivos Therapeutics Trading Down 0.6 %

VVOS stock opened at $3.53 on Thursday. The company has a market cap of $20.79 million, a price-to-earnings ratio of -0.62 and a beta of 7.47. The firm has a 50 day moving average of $4.03 and a 200-day moving average of $3.57. Vivos Therapeutics has a 12-month low of $1.91 and a 12-month high of $6.28.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets reiterated a “buy” rating and issued a $6.60 price target on shares of Vivos Therapeutics in a report on Wednesday, November 20th.

Hedge Funds Weigh In On Vivos Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC grew its holdings in Vivos Therapeutics by 23.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 26,000 shares of the company’s stock valued at $112,000 after purchasing an additional 5,000 shares during the last quarter. Cutter & CO Brokerage Inc. purchased a new stake in shares of Vivos Therapeutics in the 4th quarter worth about $163,000. Geode Capital Management LLC grew its stake in Vivos Therapeutics by 55.6% in the 4th quarter. Geode Capital Management LLC now owns 44,827 shares of the company’s stock valued at $192,000 after acquiring an additional 16,025 shares during the last quarter. Finally, Anson Funds Management LP purchased a new position in Vivos Therapeutics during the 4th quarter valued at about $1,041,000. 26.35% of the stock is owned by institutional investors and hedge funds.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.